¿ªÔÆÌåÓý

Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the Vaccine Safety Datalink, 2022-2023. 

Human Vaccines & Immunotherapeutics. 2025

Attitudes toward COVID-19 vaccines among pregnant and recently pregnant individuals. 

JAMA network open. 2024

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 

Journal of Infectious Diseases. 2024

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 

Lancet (London, England). 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 

Vaccine. 2023

Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 

American Journal of Transplantation. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons. 

Vaccine. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Racial and ethnic disparities in influenza vaccination coverage among pregnant women in the United States: the contribution of vaccine-related attitudes. 

Preventive Medicine. 2023

Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. 

Vaccine. 2023

Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. 

Vaccine. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

Developing an algorithm across integrated healthcare systems to identify a history of cancer using electronic medical records. 

Journal of the American Medical Informatics Association. 2022

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 

American Journal of Transplantation. 2022

Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 

JAMA network open. 2022

Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. 

JAMA network open. 2022

Monitoring vaccine safety using the Vaccine Safety Datalink: assessing capacity to integrate data from Immunization Information systems. 

Vaccine. 2022

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 

Vaccine. 2022

Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 

Pediatrics. 2022

Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. 

Pediatrics. 2022

Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink. 

Vaccine. 2022

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 

BMJ (Clinical research ed.). 2022

COVID-19 vaccination coverage among insured persons aged â‰�16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 

New England Journal of Medicine. 2021

Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Surveillance for adverse events after COVID-19 mRNA vaccination. 

JAMA. 2021

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. 

PloS One. 2014

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. 

Cancer Epidemiology, Biomarkers and Prevention. 2013

Oncologists' attitudes toward KRAS testing: a multisite study. 

Cancer medicine. 2013

Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. 

Genetics in Medicine. 2013

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. 

Journal of the National Cancer Institute. 2012

Barriers in identification and referral to genetic counseling for familial cancer risk: the perspective of genetic service providers. 

Journal of genetic counseling. 2011

Evaluation of EGAAP working group recommendations for identification of the Lynch Syndrome using intergenerational, microsimulation analysis [poster]

2012

Evaluation of EGAAP working group recommendations for identification of the Lynch Syndrome using intergenerational, microsimulation analysis [poster]

2012

Lynch syndrome screening patterns in colorectal cancer patients in a large multi-institutional cohort [poster]

2012

Barriers in identification, referral, counseling and testing for familial cancer: the perspective of genetic service providers [poster]

2010

Genetic service providers identify barriers related to referrals, counseling and testing for familial cancer [poster]

2010

Utilization and effectiveness of KRAS testing for colorectal cancer [poster]

2010

Chemotherapy treatment patterns among advanced colon cancer patients [abstract]. 

Clinical Medicine & Research. 2012

Current use of KRAS testing in clinical practice [abstract]. 

Clinical Medicine & Research. 2011

Comparative effectiveness research in genomics and personalized medicine for colorectal cancer [presentation], Genomic Applications in Practice and Prevention Network (GAPPNet) Annual Meeting

Genetic service providers identify barriers related to referral, counseling and testing for familial cancer [presentation], Minnesota Health Services Research 14th Annual Conference